MU down 15% on analyst HBM4 timing note with no new data. Backlogs still deep at aerospace primes. Regional banks hit by CPI, biotech off 8% on two single-stock events.
Micron Technology Inc (NASDAQ: MU) is down 15% from its high after a single analyst note questioned the timing of its HBM4 ramp, the company said in its last public guidance that the second half of 2025 would bring record revenue. The note cited no new company data.
Short interest has ticked up since the drop. Volume on the selloff was below average, a pattern traders said typically reflects position adjustments rather than new conviction shorts.
Aerospace and defense stocks took hits on two separate profit warnings and delivery delays over the past two weeks. One supplier's profit warning erased 5–10% from several names in a single session. Backlogs at major primes still run three to five years deep, the suppliers said in their filings.
Regional banks sold off after a hot CPI print pushed the 10-year yield back toward 4.5%. Higher rates compress net interest margins at smaller lenders that rely on cheap deposits. Larger diversified banks with trading desks and wealth management fees held up better, their quarterly reports showed.
Biotech fell 8% across two sessions after the FDA delayed a PDUFA date for one mid-cap oncology company and a gene-editing firm's late-stage trial missed its primary endpoint. The biotech index is still up 12% year to date. Both events were single-stock idiosyncratic, the companies said.
The S&P 500 lost 1% over the period. The Nasdaq edged slightly lower through Friday's close.
Drafted by a large language model from the source reporting linked above, then screened by automated publishing checks. It is not read by a journalist before publication. Some articles cite our Alpha Score. Verify prices and figures against the original source. Educational coverage, not personalized advice.